# Lupeol as a Potential Inhibitor of NorA Efflux Pumps in Staphylococcus aureus: In Silico and In Vitro Evidence

## TL;DR

Lupeol, a natural compound, shows potential to inhibit NorA efflux pumps in drug-resistant Staphylococcus aureus, offering a new approach to combat antibiotic resistance.

## Contribution

This study provides in vitro and in silico evidence that lupeol can inhibit NorA efflux pumps in S. aureus more effectively than a standard control.

## Key findings

- Lupeol significantly inhibits NorA efflux pump activity without damaging bacterial membrane integrity.
- Molecular docking shows lupeol binds to key residues of NorA with a binding energy of –7.112 kcal mol−1.
- Lupeol outperforms the CCCP control in inhibiting NorA efflux pump activity.

## Abstract

Antimicrobial resistance remains one of the major challenges to global public health, compromising the effectiveness of treatments and contributing to increased morbidity and mortality associated with bacterial infections. Among the mechanisms involved, efflux pumps—such as NorA, expressed in resistant strains of Staphylococcus aureus—are particularly noteworthy. These transport proteins actively expel antibiotics from the cell, reducing their intracellular concentration. In this context, natural compounds have been explored as potential resistance inhibitors, with a focus on the triterpene lupeol, known for its pharmacological properties. This study evaluates the activity of lupeol against the NorA efflux pump using in vitro assays and in silico modeling. The minimum inhibitory concentration (MIC) is determined by broth microdilution, and pump inhibition is assessed via ethidium bromide‐induced fluorescence. SYTOX Green assays indicated that lupeol does not compromise bacterial membrane integrity. Although lupeol presented a MIC ≥ 1024 μg mL−1, it demonstrates significant inhibition of NorA activity. Molecular docking reveals a binding energy of –7.112 kcal mol−1 and interactions with key residues of the protein, outperforming the CCCP control. These findings suggest that lupeol acts as a modulator of bacterial resistance, with potential application as a therapeutic adjuvant in the treatment of infections caused by multidrug‐resistant S. aureus.

© 2025 WILEY‐VCH GmbH